Feeds:
Posts
Comments

Information Security and Privacy in Healthcare is part of the 2nd Annual Medical Informatics World, April 28-29, 2014, World Trade Center, Boston, MA

Reporter: Aviva Lev-Ari, PhD

Concurrent Tracks

  • Provider-Payer-Pharma Cross-Industry Data Collaboration
  • Coordinated Patient Care Engagement and Empowerment
  • Population Health Management and Quality Improvement
  • Information Security and Privacy in Healthcare

Dinner Workshop

Advancing the Use of EHR/EMR for Clinical Research and Drug Development

About the Conference

Cambridge Healthtech Institute and Bio-IT World’s Second Annual Medical Informatics World builds upon last year’s successful inaugural launch by delivering timely programming focused on the cross-industry connections and innovative solutions needed to take biomedical research and healthcare delivery to the next level.

The 2014 meeting will bring together more than 300 senior level executives and industry leaders from each side of the discussion – providers, payers and pharma – in the fields of healthcare, biomedical sciences, health informatics, and IT. Over two days of insightful discussions and engaging presentations, leading experts will share emerging trends and solutions in population health management, payer-provider-pharma data collaborations, optimizing patient care and engagement, leveraging mobile technologies, sustaining innovation within the rapidly changing care delivery models, enhancing clinical decision support, controlling costs and improving quality, and maintaining security-privacy in healthcare. Led by key decision makers and senior executives at the forefront of healthcare information technology, the conference is a must-attend for all involved in this evolving industry.

Co-located with CHI’s flagship Bio-IT World Expo, a premier event showcasing the myriad applications of IT and informatics to the life sciences enterprise, Medical Informatics World completes the week of scientific content by bridging the healthcare and life science worlds. As Bio-IT World Expo attracts more than 2,500 delegates from dozens of countries as well as more than 130 exhibiting companies, networking opportunities abound at the two events.

KEY NOTES

John Halamka, M.D., MS, CIO, Beth Israel Deaconess Medical Center
Bryan Sivak, CTO & EIR, U.S. Department of Health and Human Services
Roy Beveridge, M.D., Senior Vice President and CMO, Humana
Mark Davies, M.D., Executive Medical Director, Health & Social Care Information Centre, National Health Service
Sachin Jain, M.D., MBA, Vice President and Chief Medical Information & Innovation Officer, Merck & Co.
Jacob Reider, M.D., Acting Principle Deputy National Coordinator, Office of the National Coordinator for Health Information Technology (ONC), U.S. Department of Health and Human Services

AGENDA

http://www.medicalinformaticsworld.com/

PROGRAM in PDF

http://www.medicalinformaticsworld.com/uploadedFiles/Medical_Informatics_World/Agenda/14/2014-Medical-Informatics-World-Conference-Brochure.pdf

 

2014 Agenda at a Glance

REAL CHALLENGES OF UNAUTHORIZED DISCLOSURE OF PHI Patient Privacy and Security: What Recent Benchmarks of Healthcare Providers Revealed Larry Ponemon, Chairman and Founder, Ponemon Institute Fair Information Practice for Cyber ID Adrian Gropper, M.D., CTO, Patient Privacy Rights Should I Trust You With My Patient’s Data? Rick Moore, CIO, National Committee for Quality Assurance (NCQA)

HITECH REGULATIONS AND THE FUTURE OF TRANSPARENCY A Practical Look at the HITECH Proposed Regulations and Federal Information Transparency Policies: The Payer Perspective Marilyn Zigmund Luke, Senior Counsel and Compliance Officer, America’s Health Insurance Plans (AHIP) Just Added! Omnibus HIPAA Rulemaking and a New Era of Privacy and Security: Don’t be an Ostrich Lassaad Fridhi, Information Privacy & Security Officer, Commonwealth Care Alliance

PUTTING HEALTHCARE DATA IN THE CLOUD Can PHI and the Cloud Coexist? Paul Connelly, Vice President, CISO, Hospital Corporation of America (HCA) Just Added! U Mass Medical College-NIH Case Study: A Privacy Solution for Sharing and Analyzing Healthcare Data Luvai Motiwalla, Ph.D., Professor, Operations and Information Systems (OIS), Manning School of Business, U Mass Lowell

BYOD: BALANCING PRIVACY, SECURITY AND FLEXIBILITY BYOD: Job Security for Privacy and Information Security Professionals Marti Arvin, Chief Compliance Officer, David Geffen School of Medicine, UCLA Health System

BYOD: BRING YOUR OWN DEVICE OR BRING YOUR OWN DISASTER? Mobile Security and BYOD in a Large Hospital System Jennings Aske, CISO, Partners HealthCare System Just Added! A Modern CISO’s Role is More than Tech: Achieving the Elusive Balance Between Information Security and Human Factors SumitSehgal, Chief Information Security & Privacy Officer, Boston Medical Center Can a Company with More than Two Million Employees Successfully Implement BYOD? Anthony Martin, Senior Associate General Counsel, Privacy & Information Security, Walmart

OVERCOMING THE INTEROPERABILITY-PRIVACY STANDOFF “Mind the Gap”: Lessons from London on Using Information to Improve English Healthcare Samantha Meikle, Director, London Connect Overcoming the Interoperability-Privacy Standoff Peter Madras, M.D., Senior Staff, Lahey Health and Hospitals; Founder, Medical Record Bank

KEYNOTE SESSION: CONNECTING PATIENTS, PROVIDERS, AND PAYERS Health Delivery Reform and the Future of Health IT-Enabled Quality Improvement Jacob Reider, M.D., Acting Principle Deputy National Coordinator, Office of the National Coordinator for Health Information Technology (ONC), U.S. Department of Health and Human Services Healthcare IT Innovations that are Connecting Patients, Providers, and Payers John Halamka, M.D., MS, CIO, Beth Israel Deaconess Medical Center Three Patients: How Health Information Technology Will Enable the Pharmaceutical Industry to Improve Patient Care Sachin Jain, M.D., MBA, Vice President and Chief Medical Information & Innovation Officer, Merck & Co. Keynote Panel: Deploying Information Technology to Enable Innovation within the Future State of Care Susan Dentzer, Senior Policy Adviser, Robert Wood Johnson Foundation

KEYNOTE SESSION: TRANSFORMING GOVERNMENT & HEALTHCARE THROUGH INNOVATION Startup Mentality: Transforming Government & Health Bryan Sivak, Chief Technology Officer & EIR, U.S. Department of Health and Human Services Humana’s Approach to Medicare Advantage Roy Beveridge, M.D., Senior Vice President and Chief Medical Officer, Humana The English Patient, a Story of NHS Informatics Mark Davies, M.D., Executive Medical Director, Health & Social Care Information Centre, National Health Service Keynote Panel: What are the Remaining Policy and Technology Barriers to Information Sharing with Patients? Daniel Sands, M.D., MPH, Assistant Clinical Professor, Harvard Medical School; Co-Founder, Society for Participatory Medicine To learn more, view the brochure or visit MedicalInformaticsWorld.com/Information-Security-Privacy.

 

————————————————————————

 

Information Security and Privacy in Healthcare is part of the Second Annual Medical Informatics World, to be held April 28-29, 2014 at the World Trade Center in Boston, MA. The event builds upon last year’s successful inaugural launch by delivering timely programming focused on the cross-industry connections and innovative solutions needed to take biomedical research and healthcare delivery to the next level. The 2014 meeting will bring together more than 300 senior level executives and industry leaders from each side of the discussion – providers, payers and pharma – in the fields of healthcare, biomedical sciences, health informatics, and IT.  Medical Informatics World Conference Tracks     Provider-Payer-Pharma Cross-Industry Data Collaboration Coordinated Patient Care, Engagement and Empowerment Population Health Management and Quality Improvement Information Security and Privacy in Healthcare   Also Available On-Site, A Dinner Workshop Advancing the Use of EHR/EMR for Clinical Research and Drug Development: A Platform that Reuses EHRs across Hospitals to Support Clinical Research supported by Sustainability Measures* (Details) > Download the full program. > For the latest speaker additions and presentation updates, visit MedicalInformaticsWorld.com. > Register now to join 300+ colleagues! > Learn more about sponsorship and exhibit opportunities.

 

SOURCE

From: Medical Informatics World 2014 <jaimeh@healthtech.com>
Date: Wed, 26 Mar 2014 11:59:00 -0400
To: <avivalev-ari@alum.berkeley.edu>
Subject: Just Added! NIH Health Privacy Case Study, Balancing Security & Human Factors, Omnibus HIPAA Rulemaking

 

Evaluate your Cas9 gene editing vectors: CRISPR/Cas Mediated Genome Engineering – Is your CRISPR gRNA optimized for your cell lines?

Reporter: Aviva Lev-Ari, PhD, RN

Theory Development:

Ribozymes and RNA Machines – Work of Jennifer A. Doudna

http://pharmaceuticalintelligence.com/2013/04/15/ribozymes-and-rna-machines-work-of-jennifer-a-doudna/

 

From Lab to Translational Medical Research to Merchandising Genomic Lab Capabilities

Is your CRISPR gRNA optimized for your cell lines?

ASC is experienced in providing guide RNA functional evaluation. ASC knows how CRISPR works – we can provide solutions.

  • Perhaps you have multiple CRISPR plasmids, but don’t know which one has the best targeting efficiency.
  • Do you want to optimize CRISPR guide RNA efficiency before you start making multiple lines with mutations?
  • Do you want to know if your guide RNA design really works (or why it did not work)?
  • Maybe your purchased CRISPR plasmids did not work to in your cells or animal models.

Our ASC CRISPR expert team can evaluate your CRISPR vectors (constructed or purchased) on your cell lines for you.

  1. Send us your vectors and cells
  2. ASC can perform evaluation testing including:

-guide RNA design consulting
-guide RNA functional test

Ask us for details (info@appliedstemcell.com).

Seminar of this week:

“CRISPR/Cas Mediated Genome Engineering in Mice” by Jax
To access the event, please go to the following link ~ 10 minutes prior to the start time and enter your username (email address). You will receive a reminder message one day prior to the event.

Thursday 27 March 2014, 01:00 PM – 02:00 PM
(GMT-05:00) Eastern Time (US and Canada)
<a href="https://emeeting.jax.org/e85utci9enl/event/login.html%20″>https://emeeting.jax.org/e85utci9enl/event/login.html <http://cts.vresp.com/c/?AppliedStemCellInc./2a297abcbb/b05fbb2164/1f925c1efd&gt;

<a href="https://emeeting.jax.org/e85utci9enl/event/login.html%20″&gt; 

Basel2014

14th ANNUAL
BIOTECH IN EUROPE FORUM
For Global Partnering & Investment

30th September – 1st October 2014 • Congress Center Basel

SACHS Associates, London

Conference website

http://www.sachsforum.com/basel14/index.html

 #Sachs14thBEF

Conference AGENDA

http://www.sachsforum.com/basel14/basel14-agenda.html

UPDATED on 8/4/2014 – SEE BELOW

http://www.sachsforum.com/basel14/Basel14-agenda.pdf

Sachs Associates is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

 

  Financial/Advisory
Investors attending
the 2014 Forum
include:
AbbVie Biotech Ventures, Inc.
Advent Life Sciences
Aescap Venture Management BV
Aglaia Biomedical Ventures B.V.
Amgen Ventures
AmorChem
apo Asset Management GmbH
Aravis AG
Aurum Ventures MKI Ltd.
Bay City Capital
BB Biotech Ventures
Bergmann zur Hausen & Cie. GmbH
BioMedPartners AG
Boehringer Ingelheim Venture Fund
Breslin AG
Capricorn Venture Partners
CD-Venture GmbH
Cederberg GmbH
CFP BioConnect AG
Citi Group
Creathor Ventures
Cukierman & Co. Life Sciences
Deutsche Bank AG
Edison Investment Research
Edmond de Rothschild Investment Partners
Ernst & Young
European Investment Fund
Excellentia Gloabl Partners
F. Hoffmann-La Roche AG Roche Venture Fund
Forbion Capital Partners
Fraser Finance
Global Life Science Ventures
HBM Partners AG
HealthCap
High-Tech Gruenderfonds Management GmbH
IBB: Venture Capital Berlin
Imperial Innovations
Industrifonden
JSB Partners LP
Knoll Capital Management
Kreos Capital
Life Sciences Partners
Lundbeckford Ventures
LSP
Medical Strategy GmbH
MedVenture Partners GmbH
MRL Ventures, Merck & Co., Inc.
MS Ventures
Nextech Invest Ltd
NGN Captial
Novartis Venture Fund
Novo A/S
NRW Bank
Omega Funds
Oriel Securities Limited
Osprey Capital Partners Inc.
Percipient Capital
Pfizer Venture Investments
Piper Jaffray
Privateq Advisors AG
Remaco AG
RMI Partners
Rosetta Capital Limited
S.R.One, Limited
SBS Investments
Seroba Kernel Life Sciences Ltd.
Siemens Technology Accelerator GmbH
Silicon Valley Bank
Sofinnova Partners
Spinnovator – Ascenion GmbH
Takeda Ventures, Inc.
TEL Venture Capital, Inc
Teralys Capital
The Welcome Trust
Torreya Partners (Europe) LLC
TVM Capital
Ventac Partners
Vesalius Biocapital
VI Partners
Vinci Capital
Visium Asset UK LLP
Warwick Ventures Ltd
Wellington Partners
XOventure GmbH
Yorkville Advisors, LLC
Ysios Capital Partners

Pharma_BI-background0238

Announcement

LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE

will cover the event for the Scientific Media

Dr. Lev-Ari will be in attendance on 9/30 and 10/1/2014 at 

Congress Center Basel, Switzerland

by

SACHS Associates, London

http://www.sachsforum.com/basel14/Basel14-agenda.pdf

 

Basel2014

14th ANNUAL
BIOTECH IN EUROPE FORUM
For Global Partnering & Investment

30th September – 1st October 2014 • Congress Center Basel

SACHS Associates, London

http://www.sachsforum.com/basel14/basel14-agenda.html

With an exciting new location, Basel, and expanded programme, we would like to invite you to join The 14th Annual Biotech in Europe Forum for Global Partnering & Investment. The Forum is recognised as the leading international stage for those interested in investing & partnering with the biotech and life science industry in Europe. There are numerous networking opportunities including a reception in the city on the evening of 30th, online 1-2-1 meeting system with meeting facilities and exhibition.

WE WOULD ALSO LIKE TO HIGHLIGHT:

  • New Panels Added for 2014

– Drug Development and Manufacturing

– Pricing and Reimbursement.

Forum Agenda Now Online – click here to view

  • Financial, Advisory and Investors Attending include:

AbbVie Biotech Ventures, Inc. • Advent Life Sciences • Aescap Venture Management BV • Aglaia Biomedical Ventures B.V. • Amgen Ventures

To view full list – click HERE  

  • Attendees:

AbbVie • Abingworth LLP • Actelion Pharmaceuticals, Ltd • ActoGeniX NV • Advent Life Sciences

To view full list – click HERE  

  • Confirmed Presenting Companies:

Actogenix NV • AFreeze GmbH • AIDD • Akron Molecules AG • AM-Pharma • AnaptysBio, Inc. • Anergis SA • APEIRON Biologics AG • APEPTICO • Arisgen SA • Asceneuron SA • B-Cell Design • BioCrea • BiolineRx • Biomay • Canbex Therapeutics Ltd. • CAP-CMV GmbH • Dana Farber Cancer Institute • Epigenomics AG • F-star Biotechnology Ltd. • Heptares Therapeutics Limited • Idera • InnoMedica Holding AG • Isarna Therapeutics • Karus Therapeutics • Lanthio Pharma • Lorus Therapeutics • MaxCyte, Inc. • Minoryx Therapeutics s.l. • Mucosis B.V. • Mymetics S.A. • NBE-Therapeutics • Neovacs • Novogen Ltd • Numab AG • Oncos Therapeutics • Opexa • Oryzon • OticPharma Ltd. • PCI Biotech • Pharmaco-Kinesis Corporation • Piqur Therapeutics AG • Re-pharm • Russian Pharmaceutical Technologies • Scancell Limited • Scil Proteins • Spectrum Pharmaceuticals • Synthena AG • Synthon Biopharma • Ugichem • VBI Vaccines • and more TBA. 

FORUM PANELS WILL INCLUDE:

  • Public Markets and M&A
  • Future of Specialty Pharma
  • Investment
  • Partnering
  • Early Stage Investment
  • Scientific Collaborations
  • Pricing and Reimbursement
  • Drug Development and Manufacturing
  • Israel
  • Specific Therapeutic Panels:

– Autoimmune & Inflammatory

– CV & Metabolic Diseases

– Infectious Diseases

– Microbiome & Nutrition

– Neuroscience – Oncology

– Personalised Medicine & Diagnostics

– Platform Technologies & Novel Therapeutics

– Vaccines

Opportunities are available for you to join the event either as a delegate, presenter or exhibitor.

Please note we have limited presenting and exhibiting opportunities available.

♦ To enquire about Attending as a delegate click HERE.

♦ To enquire about Presenting click HERE.

♦ To enquire about Exhibiting click HERE.

We have reserved a number of complimentary places for accredited investors.

♦ To enquire about an accredited investor complimentary place click HERE

_______________________________

Please find information about special negotiated rates for events attendees at the local hotels at: https://hotel.basel.com/bpf2014/E 

Confirmed Speakers & Chairs include:

Keynote Speakers:

  • Anthony Rosenberg, Head of Global M&A and Licensing, Novartis Pharma AG
  • Iris Welten, CEO, Basel Area
  • Reinhard J. Ambros, Global Head, Novartis Venture Fund

Speakers:

  • Alain Huriez, Venture Partner, Advent Life Sciences
  • Andre Hoekema, Senior Vice President Corporate Development, Galapagos
  • Andrew Macpherson, Professor Immunology, University of Bern
  • Avi Spier, Director, Strategic Alliances, Novartis Institute for BioMedical Research, Inc.
  • Barbara Dalton, VP Venture Capital, Pfizer Inc.
  • Bernard Coulie, CEO, ActoGeniX NV
  • Bernard Sixt, CEO, ImmunID
  • Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbH
  • Björn Odlander, Founding Partner, HealthCap
  • Carlos Buesa, CEO, ORYZON
  • Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
  • Chris Britten, Head, Business Development, Sanofi Pasteur MSD
  • Chris Maggos, Business Development, Alpine Institute for Drug Discovery
  • Christina Takke, Partner, Forbion Capital Partners
  • Christoph Pittius, VP, Head of Transactions, Business Development, Global Product and Portfolio Strategy, AstraZeneca
  • Corrine Savill, Head Business Development & Licensing, Novartis Pharma AG
  • Daniel Dornbusch, Chief Commercial Officer, Nodality, Inc.
  • Dan J. Gelvin, Managing Director, Life Sciences, Aurum Ventures MKI Ltd.
  • David Alderson, EU Practice Lead, Global Market Access Consulting, Evidera
  • David Colpman, Head of Global Business Development, Shire
  • Deborah Harland, General Partner, SR One
  • Dirk Beher, CEO, ASCENEURON SA
  • Prof. Edwin Constable, Head of Research, University of Basel
  • Erik van den Berg, CEO, AM-Pharma B.V.
  • Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics AG
  • Dr Fintan Walton, Founder and CEO, PharmaVentures
  • Florian Schödel, Owner, Philimmune, LLC
  • Dr Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi
  • Frank Kalkbrenner, Vice President, Head of the Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbH
  • Genghis Lloyd-Harris, Partner, Abingworth LLP

To view the full list of speakers please click HERE  

Presenting Opportunities

Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business.

Sponsorship and Exhibition

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages and exhibition packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please click the links at the top of the email or contact Mina Orda + 44 (0)203 463 4890

or by email: Mina Orda.

Warm Regards The Sachs Associates Team 27 Belsize Lane, London NW3 5AS Tel: +44 (0)203 463 4890 • Fax: +44 (0)207 691 7919 • www.SachsForum.com

To UNSUBSCRIBE click HERE

Follow us on Twitter @SachsAssociates   Sponsored and supported by:

SOURCE

From: Ann Harris <ann@sachsforum.com>
Reply-To: <ann@sachsforum.com>
Date: Tue, 17 Jun 2014 15:08:59 +0100
To: <avivalev-ari@alum.berkeley.edu>
Subject: Agenda Now Online for the 14th Annual Biotech in Europe Investor Forum

About the 14th Annual Biotech in Europe Forum

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.

The 14th Annual is held for the first time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one- to- one meetings as well as significant exhibition space. The Programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas. There will be significant networking opportunities at the Forum and receptions.

Forum Panels will include:

  • Public Markets and M&A
  • Investment
  • Partnering
  • Early Stage Investment
  • Regional Clusters
  • Future of Specialty Pharma in Europe
  • Israel
  • Scientific Collaborations
  • Pricing and Reimbursement
  • Drug Discovery and Development
  • Specific Therapeutic Panels:
    • Autoimmune & Inflammatory
    • CV & Metabolic Diseases
    • Microbiome & Nutrition
    • Infectious Diseases
    • Neuroscience
    • Oncology
    • Personalised Medicine & Diagnostics
    • Platform Technologies & Novel Therapeutics
    • Vaccines

Confirmed Speakers include:

Keynote Speakers:

  • Anthony RosenbergHead of Global M&A and LicensingNovartis Pharma AG
  • Iris WeltenCEOBasel Area
  • Reinhard J. AmbrosGlobal HeadNovartis Venture Fund

Speakers:

  • Alain HuriezVenture PartnerAdvent Life Sciences
  • Andre HoekemaSenior Vice President Corporate DevelopmentGalapagos
  • Andrew MacphersonProfessor ImmunologyUniversity of Bern
  • Avi SpierDirector, Strategic AlliancesNovartis Institute for BioMedical Research, Inc.
  • Barbara DaltonVP Venture CapitalPfizer Inc.
  • Bernard CoulieCEOActoGeniX NV
  • Bernard SixtCEOImmunID
  • Bernd GoergenInvestment DirectorHigh-Tech Gruenderfonds Management GmbH
  • Björn OdlanderFounding PartnerHealthCap
  • Carlos BuesaCEOORYZON
  • Carole NuechterleinHead of Roche Venture Fund BaselRoche Venture Fund
  • Chris BrittenHead, Business Development, Sanofi Pasteur MSD
  • Chris MaggosBusiness Development, Alpine Institute for Drug Discovery
  • Christina TakkePartner, Forbion Capital Partners
  • Christoph PittiusVP, Head of Transactions, Business Development, Global Product and Portfolio Strategy, AstraZeneca
  • Corrine SavillHead Business Development & Licensing, Novartis Pharma AG
  • Daniel DornbuschChief Commercial OfficerNodality, Inc.
  • David ColpmanHead of Global Business DevelopmentShire
  • Deborah HarlandGeneral PartnerSR One
  • Dirk BeherCEOASCENEURON SA
  • Prof. Edwin ConstableHead of ResearchUniversity of Basel
  • Erik van den BergCEOAM-Pharma B.V.
  • Esteban Pombo-VillarChief Operating OfficerOxford BioTherapeutics AG
  • Dr Fintan WaltonFounder and CEOPharmaVentures
  • Dr Frank GramsVP, Head R&D Alliance Management & ContractingSanofi
  • Frank KalkbrennerVice President, Head of the Boehringer Ingelheim Venture Fund,
    Boehringer Ingelheim GmbH
  • Genghis Lloyd-HarrisPartnerAbingworth LLP
  • Graeme MartinPresident and CEO, Takeda Research Investment
  • Graham KellyChief Executive Officer, Novogen Ltd
  • Graziano SeghezziPartner, Sofinnova Partners
  • Guillaume VignonDirector Business Development Oncology – Global Business Development and LicensingEMD Serono
  • Hakan GokerInvestment DirectorMS Ventures
  • Hamza SuriaPresident & CEOAnaptysBio, Inc.
  • Jane DancerChief Business OfficerF-star Biotechnology Ltd.
  • Janet HammondVice President, Translational Medicine – Virology in Pharmaceutical Research and Early Development (pRED)F.Hoffmann La Roche AG
  • Janis NaeveManaging DirectorAmgen Ventures
  • Jason ColomaGlobal Head Venture & Innovation at Roche Partnering,
    F.Hoffmann La Roche AG
  • Jeff BaxterCEOVBI Vaccines
  • Jesse SchulmanCEOCanbex Therapeutics Ltd.
  • Johan VerbeeckSenior Director of Partnership Management, Johnson & Johnson Innovation CenterJanssen Pharmaceutical Companies of Johnson & Johnson
  • Johannes F. ZanzingerGlobal Head, CardioMetabolic Business Development and Licensing,Boehringer Ingelheim Pharma GmbH & Co. KG
  • John GustofsonSenior Director, Venture and Early Stage ColaborationAbbVie
  • Kai BrüningSenior Portfolio Managerapo Asset Management GmbH
  • Katya SmirnyaginaPartnerCapricorn Venture Partners
  • Laurent ChoppeManaging PartnerCukierman & Co. Life Sciences
  • Laurenz KellenbergerCSOBasilea
  • Lorenza CastellonBusiness Development ConsultantSuda Ltd.
  • Lothar SteidlerVice President TechnologyActoGeniX
  • Lubor GaalHead of Europe, Strategic Transactions GroupBMS
  • Luca BolligerVP and Group Licensing DirectorRECORDATI S.A.
  • Madhusudan V. PeshwaExecutive Vice President, Cellular TherapeuticsMaxCyte, Inc.
  • Maina BhamanDirector, Healthcare VenturesImperial Innovations
  • Malcolm WeirCo-Founder and Chief Executive OfficerHeptares Therapeutics
  • Markus EwertEVP Business DevelopmentGE Healthcare
  • Matthieu CoutetManaging PartnerInserm Transfert Initiative
  • Michael J. HanewichManaging Director, Healthcare and Life Science Venture Capital,
    Silicon Valley Bank
  • Michael ShalmiSenior PartnerNovo A/S
  • N. Roa MovvaNovartis Distinguished Scientist, Executive Director,
    DMP/NIBR/Novartis Pharma AG
  • Nicholas FrancoExecutive Vice President & Chief Business Development Officer,
    Actelion Pharmaceuticals, Ltd
  • O. Prem DasChief Research Business Development Officer and Heads DFCI’s Office of Research and Technology Ventures (ORTV)Dana-Farber Cancer Institute (DFCI)
  • Oliver MiddendorpCo-CEO & CBONumab AG
  • Peter BurckhardtChief Executive OfficerEVA – the Basel life sciences start-up agency
  • Philip A. SerlinChief Financial and Operating OfficerBioLineRx, Ltd.
  • Philippe CalaisCEOIsarna Therapeutics GmbH
  • Philippe Lopes-FernandesSenior Vice-President, Head of Global Licensing & Business DevelopmentMERCK KGaA / EMD
  • Pierre VandepapeliereCMONeovacs
  • Rainer HenningCEOBiomay AG
  • Rainer MetzgerVP Global Business Development PharmaQIAGEN GmbH
  • Rainer StrohmengerGeneral PartnerWellington Partners
  • Reid J. LeonardManaging DirectorMRL Ventures, Merck & Co., Inc.
  • Richard GoodfellowCEOScancell Holdings plc
  • Robin DavisonDirector, HealthcareEdison Investment Research
  • Søren MøllerManaging Investment DirectorNovo Seeds
  • Stefan FringsGlobal Head, Oncology Immunology Therapeutic AreaRoche
  • Stephanie LéouzonPrincipal and Head of Torreya Partners EuropeTorreya Partners
  • Stewart KayDirector Transactions, Worldwide Business DevelopmentGSK
  • Susan HillDirector of Global Business DevelopmentAlexion Pharma International Sarl
  • Thomas StockmanDirector, Healthcare Investment BankingCiti Group
  • Tim HerpinVice President, Head of Transactions (UK), Business DevelopmentAstraZeneca
  • Tim KnotnerusDirector Business DevelopmentAm-Pharma
  • Tom JohnstonCEOMucosis B.V.
  • Tom KronbachCEOBioCrea
  • Tomas LandhDirector, Strategy and Innovation SourcingNovo Nordisk
  • Ulf GrawunderCEONBE-Therapeutics Ltd
  • Vincent CharlonCEOAnergis SA
  • Vladimir CmiljanovicCEOPIQUR Therapeutics AG
  • Wilder FulfordPrincipalTorreya Partners (Europe) LLC
  • And More TBA…

Presenting Opportunities

Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business.

Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.

The forum is recognised as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners.

Sponsorship

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact
Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda.

 

SOURCE

http://www.sachsforum.com/basel14/index.html

Editorials of event coverage via our Open Access Scientific Journal

http://pharmaceuticalintelligence.com

Scientific Journal Site Statistics

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

07/29/2013   217,356 1,138 1,389 705
12/01/2013   287,645 1,428 1,676 828
02/09/2014   325,039 1,665 1,793 892
03/05/2014   338,958 1,717 1,830 965
03/21/2014   347,667 1,750 1,838 974

03/31/2014  352,683 1,768 1,869 991

05/12/2014  373.696  1,878  1,944  1,035

06/18/2014  393,111  1,992  1,982  1,087

7/27/2014  418,570  2,098  2.050  1,124

9/2/2014  444,222  2,226  2,104  1,170

09/02/2014  

444.222 Views  

2,226 Articles  

NATURE clicks 1,170

ncbi.nlm.nih.gov clicks  2,104

fda.gov  clicks 198

cancer.gov  clicks  162

 

Pre e-Pub e-Books Flyers

 

Series C: e-Books on Cancer & Oncology

Volume One: Cancer Biology and Genomics for Disease Diagnosis

http://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-biology-and-genomics-for-disease-diagnosis/

Volume Two: Therapies in Cancer – Surgery, Radiation, Chemo and Immunotherapies

http://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/volume-2-immunotherapy-in-oncology/

Series B: Frontiers in Genomics Research

Volume One: Genomics Orientations for Individualized Medicine

http://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

GENOMICS related articles in the JOURNAL

  • Cardiovascular Pharmacogenomics – 134 articles
  • Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics – 55 articles
  • Nutrigenomics – 43 articles
  • Pharmacogenomics – 88 articles
  • Genomic Testing: Methodology for Diagnosis – 241 articles
  • Personalized Medicine & Genomic Research – 390 articles
  • Genome Biology – 421 articles

Genomics Orientations for Individualized Medicine

Volume One

genomicsebook31

Exploring the Impact of Content Curation on Business Goals in 2013

Reporter: Aviva Lev-Ari, PhD, RN

 

Full Account:

http://stuff.scoop.it/nl/upload/pdf/Impact_of_Content_Curation_on_Business_Goals_in_2013.pdf

 

www.scoop.it

 

Exploring the impact of content curation on business goals in 2013

Content curation seems to have been one of the biggest marketing buzzwords of 2013. Hundreds of experts are telling businesses both small and large that content curation is the secret to success in content marketing and it’s time to get

Almost an entire quarter into 2014, it’s time to take “getting started” to the next level. Scoop.it surveyed professionals who have been using content curation as a part of their marketing strategy for the past year in order to discover its impact on business goals.

It just works

Scoop.it surveyed 1,550 professionals between October of 2013 and January of 2014 in order to gain a better understanding of their most important business goals as well as the challenges that these professionals are facing in accomplishing these

It’s been established many times that modern day professionals struggle to find the time to create original content, maintain their online presences, and keep track of the ever-increasing amount of information available on various topics. When taken a step further though, the findings demonstrate that more than half of professionals find solutions to these and other pain points through the use of content curation.

Many reports have emphasized the perceived importance of content curation, but for the first time ever, we’ve got quantitative proof that it works.

Overall, the findings demonstrate measurable business results as a result of content curation, and an even higher perceived value of curation for the upcoming business year.

 

What does it all mean?

The industry has reached a point in time where professionals no longer have to guess about the impact that content curation will have on reaching business goals and solving the issues faced by a vast majority of content marketers.

There is strong evidence in support of the business benefits of adding content curation to the content marketing mix. This report has taken the guesswork out of evaluating curation as a potential tool for accomplishing common goals like building engaged audiences, brand awareness, SEO, thought leadership and educating audiences by organizing large amounts of relevant content in a meaningful way.

93% of digital professionals surveyed plan on seeing a measurable impact from content curation in the upcoming year simply based upon the successes they saw during their first year using it.

 

Take the next step

There are endless resources available for professionals to begin learning about content curation, and it still isn’t too late to launch a curation-based strategy for 2014.

Begin feeding your content marketing needs today for better results tomorrow. Say bye to the buzzword and find out how Scoop.it can help you get the ball rolling.

SOURCE

From: “<Ally Greer>” , “Scoop.it” <contact@scoop.it>
Reply-To: “<Ally Greer>” , “Scoop.it” <contact@scoop.it>
Date: Tue, 25 Mar 2014 19:53:21 +0000
To: <avivalev-ari@alum.berkeley.edu>
Subject: FREE REPORT: Impact of curation on business goals

See on Scoop.itCardiotoxicity

Shared with Dropbox (RT @MoveTheMedian: Health pros often need to help clients with medication compliance. health coaches can help.

See on www.dropbox.com

See on Scoop.itCardiotoxicity

Family Medicine – Focus on…Medical Article: Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults (Antihypertensive medications and serious fall injuries in a nationally representative sample…

See on www.mdlinx.com

See on Scoop.itCardiovascular and vascular imaging

El Aidi H, Adams A, Moons KG, Den Ruijter HM, Mali WP, Doevendans PA, Nagel E, Schalla S, Bots ML, Leiner T.
J Am Coll Cardiol. 2014; 63(11):1031-1045.

See on www.thepreparedminds.com

Technology: With a unique program, the US government has managed to drive the cost of genome sequencing down to $1,000

Reporter: Aviva Lev-Ari, PhD, RN

 

See on Scoop.itCardiovascular and vascular imaging

With a unique program, the US government has managed to drive the cost of genome sequencing down towards a much-anticipated target.

 

The quest to sequence the first human genome was a massive undertaking. Between 1990 and the publication of a working draft in 2001, more than 200 scientists joined forces in a $3-billion effort to read the roughly 3 billion bases of DNA that comprise our genetic material (International Human Genome Sequencing Consortium Nature 409, 860–921; 2001).

 

It was a grand but sobering success. The project’s advocates had said that it would reveal ‘life’s instruction book’, but in fact it did not make it possible to interpret how the instructions encoded in DNA were transformed into biology. Understanding how DNA actually influences health and disease would require studying examples of the links between genes and biology in thousands, perhaps millions, more people. The dominant technology at the time was Sanger sequencing, an inherently slow, labour-intensive process that works by making copies of the DNA to be sequenced that include chemically modified and fluorescently tagged versions of the molecule’s building blocks. One company, Applied Biosystems in Foster City, California, provided the vast majority of the sequencers to a limited number of customers — generally, large government-funded laboratories — and there was little incentive for it to reinvent its core technology.

 

A $7-million award from the NHGRI allowed the company to commercialize a technology called pyrosequencing, which was the first to begin chipping away at Applied Biosystems’ monopoly. The funding commitments also ultimately helped to convince private investors to enter the market. Stephen Turner, founder and chief technology officer of Pacific Biosciences in Menlo Park, California, says that his company’s 2005 NHGRI grant of $6.6 million helped to attract subsequent venture-capital funding.

 

The government program has invested $88 million in technologies based on nanopores and nanogaps. The form of this technology closest to the market involves reading bases as they are threaded through a pore (see Nature 456, 23–25; 2008), a method that has long promised to save costs and time by reading DNA while it is processed. It would negate the need for expensive and slow reactions to make lots of copies of the molecule. But solving basic issues, including how to move the DNA through the pore slowly enough, has been a major challenge. The NHGRI has funded work to overcome these hurdles — including $9.3 million given to collaborators of the company now ushering the concept to market, UK-based Oxford Nanopore Technologies (Nature http://doi.org/rvm; 2014).

 

Sequencing still needs much improvement, especially in terms of quality. For all of Sanger sequencing’s high cost, it remains the benchmark for accuracy. And sequencing costs are no longer dropping as quickly as they were a few years ago.

 

But researchers are optimistic that another technology will emerge to challenge Illumina. Most think, in fact, that the crucial questions for the field will shift away from technology. Now that sequencing is cheap enough to talk about scanning every patient’s genome, or at least the protein-coding portion of it, it is still not clear how that information will translate into improved care (Nature http://doi.org/rvq; 2014). These more complex issues will require another great leap in genomic science — one that could make the trouncing of Moore’s law seem easy

 

See on www.nature.com

See on Scoop.itCardiovascular and vascular imaging

Studies have demonstrated that mesenchymal stromal cells (MSCs) could reverse acute and chronic kidney injury by a paracrine or endocrine mechanism, and microvesicles (MVs) have been regarded as a crucial means of intercellular communication.

See on stemcellres.com

Natural Drug Target Discovery and Translational Medicine in Human Microbiome

Author and Curator: Demet Sag, PhD

 

Remember Ecology 101, simple description of ecosystem includes both living, biotic, and non-living, abiotic, that response to differentiation based on external and internal factors.  Hence, biodiversity changes since living systems are open systems and always try to reach stability. Both soil and human body are rich in microbial life against ever changing conditions. Previously, discovery of marine microorganisms for treatment of complex diseases especially cancer and drug discovery for pharmaceutical applications was discussed. (http://pharmaceuticalintelligence.com/2014/03/20/without-the-past-no-future-but-learn-and-move-genomics-of-microorganisms-to-translational-medicine/)

Here, the focus will be given to clinical drug discovery based on how lactose intolerance and human microbiome related to treat cancer patients or other diseases. In sum, creating clinical relevance with human microbiome require knowledge of both of the worlds to make best of it to solve complex diseases naturally.

The huge undertake as a roadmap to biomedical research originated by NIH under The Human Microbiome Project (HMP) (http://nihroadmap.nih.gov) with 250 healthy individuals as a starting point.  Recent developments opened the doors to pursue us to understand how human microbiome reflects on metabolism, drug interactions and numerous diseases.  Finally, association between clinical states and microbiome are improving with advanced algorithms, bioinformatics and genomics. In classical reading tests questions finding the simile between two groups of words can well relate how microbiome- human and soil-earth relates.  Both are rich in microbial life with quite changing characters to survive through commensal living.

Thus, it is also good to talk about how we can synthesize existing info on interactions between soil microorganisms and decomposers for human diseases and human microbiome. Epidemiology of living organisms is diverse but they all share common interest. In soil, for example, radioactively contaminated soil can’t support plant growth well so Nitrosomonas may support to bring the life to soil through supplying nitrogen. And others can be added to bring a favorable enriched soil.

In human microbiome nutrition-diseases interacts in such a harmony with genetic make up (the information received at time of birth germline- or acquired later in life due to mutations by various reasons). For example, the simplest example is lactose intolerance and the other is development of diabetes.  Generally, it is described as If person is missing a gene to metabolize lactose (sugar) this person become Lactose intolerant yet this can be gained before birth or after. The fix is easy since avoiding certain food groups i.e. milk products.

Yet, this is not that simple!

In human microbiome, the rich gastrointestinal (GI) tract contains many organisms and one of the most important ones is Enterococci that are often simply described as lactic-acid–producing bacteria—by under- appreciation of their power of microbial physiology and outcomes as well as their ubiquitous nature of enterococci.  Schleifer & Kilpper-Bälz, 1984 also reported that the Group D streptococci, such as Streptococcus faecalis and Streptococcus faecium, were included in the new genus called Enterococcus.

The importance of this genius, consists of 37 species, coming from their spectrum of  habitats that include the gastrointestinal microbiota of nearly every animal phylum and flexibility with ability to widely colonize, intrinsic resistance to many inhabitable conditions even though they don’t have spores but they can survive against desiccation and can persist for months on dried surfaces.  Furthermore, they can tolerate extreme conditions such as pH changes, ionizing radiation, osmotic and oxidative stresses, high heavy metal concentrations, and antibiotics.

There is a double sword application as these organisms used as probiotics to improve immune system of the host.  If it is human to prevent contaminated food related diseases or in animals prevent transmitting them to the consumers. Thus, E. faecium and E. faecalis strains are used as probiotics and are ingested in high numbers, generally in the form of pharmaceutical preparations to treat diarrhea, antibiotic-associated diarrhea or irritable bowel syndrome, to lower cholesterol levels or to improve host immunity.

When it comes to human body within each system specific organs may create distinct values.  For example the pH values of GI tract vary and during diseases since pH levels are not at at correct levels.  As a result, due to mal-absorption of nutrients and elements such as food, vitamins and minerals body can’t heal itself. This changing microbial genomics on the surface of GI reflects on general health.  Entrococcus family among the other GI’s natural flora has the microbial physiology adopt these various pH conditions well. 

 

Our body has its own standards to function, such as  pH, temperature, oxygen etc these are basics so that enzymatic reactions may happen to metabolize,synthesizing (making) or catalyzing (breaking) what we eat.  The pH is the measure of hydrogen-ion concentration  in solution.  For example, human blood has a narrow pH (7.35 – 7.45 ) and below or above this range means symptoms and disease yet if blood pH moves to much below 6.8 or above 7.8, cells stop functioning and the patient dies since the ideal pH for blood is 7.4.  This value is unified.  On the other hand, the pH in the human digestive tract or GI changes tremendously to adopt and carry on its function, the pH of saliva (6.5 – 7.5), upper portion of the stomach (4.0 – 6.5) where “predigestion” occurs, the lower portion of the stomach is secreting hydrochloric acid (HCI) and pepsin until it reaches a pH between 1.5 – 4.0; duodenum, small intestine, (7.0 – 8.5) where 90% of the absorption of nutrients is taken in by the body while the waste products are passed out through the colon (pH 4.0 – 7.0).

 

Why is pH important and how related to anything?

Development and presence of cancer always require an acid pH and lack of oxygen.  Thus, prevention of these two factors may be the key for treatment of cancer as it progress the acidity increases such that the level raises even up to 1000 more than normal levels.

Mainly, due to Warburg effect body opt to get its energy from fermentation of glucose and produce lactic acid that decreases the body pH from 7.3 down to 7 then to 6.5 in advanced stages of cancer.  Furthermore, during metastases this level even reaches to 6.0 and even 5.7 where body can’t fight back with the disease. (Warburg effect is well explained previously by Dr. Larry Berstein (www.linkedin.com/pub/larry-bernstein/38/94b/3aa).

How to bypass the lack of oxygen naturally?

One of the many solution can be a natural solution. The nature made the hemoglobin carrying bacteria, Vitreoscilla hemoglobin (VHb), which is first described by Dale Webster in 1966. The gram negative and obligate aerobic bacterium, Vitreoscilla synthesizes elevated quantities of a homodimeric hemoglobin (VHb) under hypoxic growth conditions.   The main role is likely the binding of oxygen at low concentrations and its direct delivery to the terminal respiratory oxidase(s) such as cytochrome o.  Then, after 1986 with detailed description of the molecule other hemoglobins and flavohemoglobins were identified in a variety of microbes, indicating the widespread occurrence of Hb-like proteins.   Currently, it is the most studied bacterial hemoglobin with application potentials in biotechnology.

It is a plausible solution to integrate Vitroscilla and Enterobacter powers for cancer detection and treatment naturally with body’s own microbiome.

However, there are many microbial organisms and differ person to person based on gender, age, background, genetic make-up, food intake, habits, location etc.  The huge undertake as a roadmap to biomedical research originated by NIH under The Human Microbiome Project (HMP) (http://nihroadmap.nih.gov) with 250 healthy individuals as a starting point.

There were three goals in the agenda of The Human Microbiome Project (HMP) simply:

 1. Utilize advanced high throughput technology,

2. Identify any association between microbiome and disease/health stages,

3. Initiate scientific studies to collect more data.

In sum, creating clinical relevance with human microbiome require knowledge of both of the worlds to make best of it to solve complex diseases naturally.

Previously  Discussed:

AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Reporter-Curator: Stephen J. Williams, Ph.D.
http://pharmaceuticalintelligence.com/2013/03/12/ampk-is-a-negative-regulator-of-the-warburg-effect-and-suppresses-tumor-growth-in-vivo/

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?
Author: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/10/17/is-the-warburg-effect-the-cause-or-the-effect-of-cancer-a-21st-century-view/

Otto Warburg, A Giant of Modern Cellular Biology
Reporter: Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/11/02/otto-warburg-a-giant-of-modern-cellular-biology/

Targeting Mitochondrial-bound Hexokinase for Cancer Therapy
Author: Ziv Raviv, PhD
http://pharmaceuticalintelligence.com/2013/04/06/targeting-mito…cancer-therapy

Nitric Oxide has a ubiquitous role in the regulation of glycolysis -with a concomitant influence on mitochondrial function
Curator, Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/09/16/nitric-oxide-has-a-ubiquitous-role-in-the-regulation-of-glycolysis-with-a-concomitant-influence-on-mitochondrial-function/

Potential Drug Target: Glucolysis Regulation – Oxidative stress-responsive microRNA-320
Reporter: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2012/07/25/potential-drug-target-glucolysis-regulation-oxidative-stress-responsive-microrna-320/

Differentiation Therapy – Epigenetics Tackles Solid Tumors
Author-Writer: Stephen J. Williams, Ph.D.
http://pharmaceuticalintelligence.com/2013/01/03/differentiation-therapy-epigenetics-tackles-solid-tumors/

Prostate Cancer Cells: Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition
Reporter-Curator: Stephen J. Williams, Ph.D.
http://pharmaceuticalintelligence.com/2012/11/30/histone-deacetylase-inhibitors-induce-epithelial-to-mesenchymal-transition-in-prostate-cancer-cells/

Mitochondrial Damage and Repair under Oxidative Stress
Curator: Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/10/28/mitochondrial-damage-and-repair-under-oxidative-stress/

Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation
Curator: Larry H Bernsatein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/09/26/mitochondria-origin-from-oxygen-free-environment-role-in-aerobic-glycolysis-metabolic-adaptation/

Expanding the Genetic Alphabet and Linking the Genome to the Metabolome
Reporter& Curator: Larry Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/09/24/expanding-the-genetic-alphabet-and-linking-the-genome-to-the-metabolome/

What can we expect of tumor therapeutic response?
Author: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/12/05/what-can-we-expect-of-tumor-therapeutic-response/

A Second Look at the Transthyretin Nutrition Inflammatory Conundrum
Larry H. Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/12/03/a-second-look-at-the-transthyretin-nutrition-inflammatory-conundrum/

 

Further  Readings and References:

Palmer KL, van Schaik W, Willems RJL, Gilmore MS. “Enterococcal Genomics Enterococci: From Commensals to Leading Causes of Drug Resistant Infection.” 2014-.2014 Feb 8

Franz CM, Holzapfel WH, Stiles ME. Enterococci at the crossroads of food safety?

Int J Food Microbiol.” 1999 Mar 1; 47(1-2):1-24.

Franz CM, Huch M, Abriouel H, Holzapfel W, Gálvez A.Int J Food Microbiol. “Enterococci as probiotics and their implications in food safety.” 2011 Dec 2; 151(2):125-40. Epub 2011 Sep 8.

Kayser FH.”Safety aspects of enterococci from the medical point of view.” Int J Food Microbiol. 2003 Dec 1; 88(2-3):255-62.

Webster DA, Hackett DP (1966). “The purification and properties of cytochrome o fromVitreoscilla“. J Biol Chem 241 (14): 3308–3315

Stark BC, Dikshit KL, Pagilla KR (2011). “Recent advances in understanding the structure, function, and biotechnological usefulness of the hemoglobin from the bacterium Vitreoscilla“. Biotechnol Lett 33 (9): 1705–1714

Stark BC, Dikshit KL, Pagilla KR (2012). “The Biochemistry  of Vitreoscillahemoglobin“. Computational and Structural Biotechnology Journal 3 (4): e201210002.

Brenner K, You L, Arnold F. (2008). “Engineering microbial consortia: A new frontier in synthetic biology.” Trends in Biotechnology 26: 483489.

Dunbar J, White S, Forney L. (1997). “Genetic diversity through the looking glass: Effect of enrichment bias.Applied and Environmental Microbiology 63: 13261331.

Foster J. (2001). “Evolutionary computation Nature Reviews Genetics 2: 428436.

Dinsdale EA, et al. 2008. “Functional metagenomic profiling of nine biomes.” Nature452: 629632.

Gudelj I, Beardmore RE, Arkin SS, MacLean RC. (2007). “Constraints on microbial metabolism drive evolutionary diversification in homogeneous environments.” Journal of Evolutionary Biology 20: 1882–1889.

Haack SK, Garchow H, Klug MJ, Forney L. (1995). “Analysis of factors affecting the accuracy, reproducibility, and interpretation of microbial community carbon source utilization patterns.” Applied and Environmental Microbiology 61: 14581468.

Lozupone C, Knight R. (2007). “Global patterns in bacterial diversity.” Proceedings of the National Academy of Sciences 104: 1143611440.

Thurnheer T, Gmr R, Guggenheim B,  (2004). “Multiplex FISH analysis of a six-species bacterial biofilm. “Journal of Microbiological Methods 56: 3747.

VijayKumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S,Sitaraman S, Knight R, Ley RE, Gewirtz AT. (2010). “Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5.” Science 328: 228231

Williams HTP, Lenton TM. (2007). “Artificial selection of simulated microbial ecosystems.” Proceedings of the National Academy of Sciences 104: 89188923.